New Republic Capital’s AstraZeneca AZN Stock Holding History

New Republic Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$558K	Buy	2,942 +219	+8%	+$41.2K	0.13%	129
2026 Q1	$537K	Sell	2,723 -1,683	-38%	-$325K	0.18%	105
2025 Q4	$810K	Buy	4,406 +2,644	+150%	+$464K	0.22%	89
2025 Q3	$270K	Buy	1,762 +298	+20%	+$45.1K	0.08%	148
2025 Q2	$205K	Sell	1,464 -90	-6%	-$12.6K	0.07%	174
2025 Q1	$228K	Sell	1,554 -172	-10%	-$24.9K	0.1%	154
2024 Q4	$226K	Buy	+1,726	New	+$242K	0.15%	149
2024 Q3	–	Sell	-1,394	Closed	-$217K	–	241
2024 Q2	$217K	Buy	+1,394	New	+$210K	0.11%	162

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

New Republic Capital's AZN Position: Q2 2026 in Review

New Republic Capital increased its AstraZeneca (AZN) stake by 8% in Q2 2026, buying an estimated $41.2K and bringing the position to 2,942 shares worth $558K. The position accounts for 0.13% of the portfolio, ranked #129.

New Republic Capital first reported a position in AZN in Q2 2024 and has held it in 8 quarters since. The position peaked at $810K in Q4 2025. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

New Republic Capital held 2,942 shares of AstraZeneca worth $558K as of Q2 2026.
New Republic Capital bought 219 AstraZeneca shares in Q2 2026, an estimated $41.2K.
AstraZeneca made up 0.13% of New Republic Capital's portfolio in Q2 2026, its #129 holding.
New Republic Capital first reported a position in AstraZeneca in Q2 2024 and has held it in 8 quarters since.
New Republic Capital's AstraZeneca position peaked at $810K in Q4 2025.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on New Republic Capital's 13F filing for Q2 2026, filed 31 Jul 2026.